Healthcare >> CEO Interviews >> August 6, 2001
PHILIP N. SUSSMAN was appointed President and CEO of SIGA Technologies,
Inc., in June 2001. He was previously Executive Vice President'Corporate
Development at Memory Pharmaceuticals Corp., a privately-held
biopharmaceutical company. From 1993 to 1999 he was an Officer at Cadus
Pharmaceutical Corporation, rising to the position of Senior Vice
President'Finance and Corporate Development and Chief Financial Officer.
Prior to that he was Director of Strategy and Business Development at
Ciba-Geigy Corp.'s (now Novartis Corp.) Pharmaceuticals Division. Mr.
Sussman is a member of the Review Panel for the Innovative Technology
Research Grant Program, Center for Biotechnology, New York State Science
and Technology Foundation. He is also an author of recent articles in
Scrip magazine, The Journal of BioLaw & Business, and Journal of
Commercial Biotechnology, where he is a member of the Editorial Board.
He holds an SM in Management with a concentration in Finance from the
Sloan School of Management at the Massachusetts Institute of Technology,
an MS degree in Biotechnology from Manhattan College, and a BS degree in
Physics from the State University of New York at Stony Brook. Profile
Technologies?
Mr. Sussman: SIGA Technologies had a reconstitution of its board in
April. As a result of that, Donald Drapkin
